An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum.
An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum.
复制标题
DOI：
10.1016/j.jacl.2017.10.022
复制
发表时间：
2018-01
影响因子：
4.4
通讯作者：
Nakajima K
中科院分区：
文献类型：
--
作者：
Miyashita K;Fukamachi I;Nagao M;Ishida T;Kobayashi J;Machida T;Nakajima K;Murakami M;Ploug M;Beigneux AP;Young SG;Nakajima K
GPIHBP 1是毛细血管内皮细胞的糖基磷脂酰肌醇（GPI）锚定蛋白，其将脂蛋白脂肪酶转运至毛细血管腔，并且对于富含磷脂酰肌醇的脂蛋白的脂解加工是必需的。由于在血浆中检测到一些GPI锚定蛋白，我们测试了GPIHBP 1是否存在于人类血液中，以及GPIHBP 1缺乏或心血管疾病史是否影响GPIHBP 1循环水平。我们研制了两株抗GPIHBP 1的单克隆抗体，并建立了检测人血中GPIHBP 1水平的夹心ELISA方法。GPIHBP 1 ELISA在8-500 pg/ml范围内呈线性，可定量测定血清以及肝素给药前和给药后血浆（包括脂血样本）中的GPIHBP 1。GPIHBP 1无效突变受试者血浆中检测不到GPIHBP 1。健康志愿者（n = 28）的血清GPIHBP 1中位数水平为849 pg/ml（范围：740-1014），有心血管或代谢疾病史的患者（n = 415）的血清GPIHBP 1中位数水平为1087 pg/ml（范围：877-1371）。GPIHBP 1与甘油三酯呈极显著负相关（r = 0.109; P <0.0275）。GPIHBP 1水平在血运重建后发生重大心血管事件的患者中略高。我们开发了一种定量人血液中GPIHBP 1的ELISA。该检测将有助于识别GPIHBP 1缺陷患者和GPIHBP 1自身抗体患者。血浆GPIHBP 1作为代谢或心血管疾病的生物标志物的潜力尚不确定，但需要额外的测试。
GPIHBP1, a glycosylphosphatidylinositol (GPI)-anchored protein of capillary endothelial cells, transports lipoprotein lipase to the capillary lumen and is essential for the lipolytic processing of triglyceride-rich lipoproteins. Because some GPI-anchored proteins have been detected in plasma, we tested whether GPIHBP1 is present in human blood, and whether GPIHBP1 deficiency or a history of cardiovascular disease affected GPIHBP1 circulating levels. We developed two monoclonal antibodies against GPIHBP1and used the antibodies to established a sandwich ELISA to measure GPIHBP1 levels in human blood. The GPIHBP1 ELISA was linear in the 8–500 pg/ml range and allowed the quantification of GPIHBP1 in serum and in pre- and post-heparin plasma (including lipemic samples). GPIHBP1 was undetectable in the plasma of subjects with null mutations in GPIHBP1. Serum GPIHBP1 median levels were 849 pg/ml (range: 740–1014) in healthy volunteers (n = 28) and 1087 pg/ml (range: 877–1371) in patients with a history of cardiovascular or metabolic disease (n = 415). There was an extremely small inverse correlation between GPIHBP1 and triglyceride levels (r = 0.109; P <0.0275). GPIHBP1 levels tended to be slightly higher in patients who had a major cardiovascular event after revascularization. We developed an ELISA for quantifying GPIHBP1 in human blood. This assay will be useful to identify patients with GPIHBP1 deficiency and patients with GPIHBP1 autoantibodies. The potential of plasma GPIHBP1 as a biomarker for metabolic or cardiovascular disease is yet questionable but needs additional testing.
登录
查看更多内容
影响因子：
20.1
作者：
Beigneux AP;Fong LG;Bensadoun A;Davies BS;Oberer M;Gårdsvoll H;Ploug M;Young SG
通讯作者：
Young SG
影响因子：
4.8
作者：
Plengpanich, Wanee;Young, Stephen G.;Beigneux, Anne P.
通讯作者：
Beigneux, Anne P.
影响因子：
6.5
作者：
Olivecrona, Gunilla;Ehrenborg, Ewa;Hernell, Olle
通讯作者：
Hernell, Olle
影响因子：
1.6
作者：
Gardsvoll, Henrik;Hansen, Line V.;Ploug, Michael
通讯作者：
Ploug, Michael
DOI：
10.1161/atvbaha.109.186577
发表时间：
2009-06
期刊：
Arteriosclerosis, thrombosis, and vascular biology
影响因子：
--
作者：
Beigneux AP;Franssen R;Bensadoun A;Gin P;Melford K;Peter J;Walzem RL;Weinstein MM;Davies BS;Kuivenhoven JA;Kastelein JJ;Fong LG;Dallinga-Thie GM;Young SG
通讯作者：
Young SG